Inozyme Pharma to Present Recently Announced Preliminary Data from Ongoing Phase 12 Trial in ENPP1 Deficiency at the European Calcified Tissue Society Congress ECTS

BOSTON, April 14, 2023 (GLOBE NEWSWIRE) — Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced Yves Sabbagh, Ph.D., the company’s senior vice president and chief scientific officer, will present recently announced preliminary data…Read More